BTG (BTG)

 

BTG Share PerformanceMore

52 week high739.5 12/07/16
52 week low528.4 31/01/17
52 week change -40.5 (-6.05%)
4 week volume22,105,802 29/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

BTG unveils results of OPTALYSE PE study

BTG (LSE: BTG) has highlighted the results of the OPTALYSE PE trial, presented at the American Thoracic Society Intern...

BTG OPTALYSE PE Study

RNS Number: 8184F BTG PLC 22 May 2017 OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS Therapy For Pulmonary Embolism Bothell, WA, 22 May 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the OPTALYSE PE trial, presented at the American Thoracic Society Internati...

Broker Forecast - Panmure Gordon issues a broker note on BTG PLC

Panmure Gordon today reaffirms its buy investment rating on BTG PLC (LON:BTG) and cut its price target to 793p (from...

Fund manager's favourite small-cap pharma shares

If you're looking for capital growth, don't bother with big pharma, argues fund manager Paul Mumford. He tells Lee Wild...

Broker Forecast - Peel Hunt issues a broker note on BTG PLC

Peel Hunt today reaffirms its hold investment rating on BTG PLC (LON:BTG) and raised its price target to 680p (from 630...

Additional Listing

RNS Number: 4166F BTG PLC 17 May 2017 17 May 2017 BTG plc - Additional Listing BTG plc (LSE:BTG) announces that application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 650,000 ordinary shares of 10 pence each under the BTG Performance Share Plan, 21,000 ordinary shares of 10 pence each under the BTG...

Broker Forecast - JP Morgan Cazenove issues a broker note on BTG PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on BTG PLC (LON:BTG) and cut its price target to 750...

Broker Forecast - Panmure Gordon issues a broker note on BTG PLC

Panmure Gordon today reaffirms its buy investment rating on BTG PLC (LON:BTG) and raised its price target to 809p (fr...

Fundamental DataMore

P/E ratio39.81
EPS15.8
Dividend yield0 %

Equity Research (BTG)

edison investment research
BTG plc
08/04/2016
Growth across all three divisions of BTG’s Interventional Medicine (IM) franchise (oncology, vascular and pulmonology), coupled with currency tailwinds, helped push FY16 revenue towards the upper end...
edison investment research
BTG plc
30/11/2015
BTG’s interim results have driven upgrades to our financial forecasts with a small boost to revenues from one-off Zytiga backdated royalties. Our operating expenses are broadly unchanged, but...
edison investment research
BTG plc
30/10/2015
BTG’s close period update saw a revision to its FY16 revenue guidance, targeting sales in the lower half of £410-440m (at $1.61/£). This is based on slower-than-expected Varithena sales, despite a...

Latest discussion posts More

  • now i understand

    The stock is not going anywhere until the recent acquisitions and varithena for faty people takes off. Institions will hold then sell out . INMO the thing to look for is ...
    23-May-2017
    up protherics
  • OPTALYSE PE Study for Lower Dose EKOS?

    OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS? Therapy For Pulmonary Embolism Bothell, WA, 22 May 2017: BTG plc (LSE: BTG), the global ...
    22-May-2017
    d gaser
  • Share price

    So we go up and then as Usaul we drip down !! Is this the most frautrauting share ever ?? Me De Gasser et al have held for over 10 years !! Yes we bought in at 70p and no ...
    22-May-2017
    pauloverdi

Users' HoldingsMore

Users who hold BTG also hold..
LLOYDS GRP.33%
NATIONAL GRID25%
GLAXOSMITHKLINE25%
VODAFONE GRP.23%
BP23%

Codes & Symbols

ISINGB0001001592
SymbolsBTG, LSE:BTG, BTG.L, BTG:LN, LON:BTG, XLON:BTG